Senseonics Stock Price, News & Analysis

Senseonics Holdings, Inc. (SENS) is a medical technology company in the surgical and medical instrument manufacturing industry. According to company disclosures, Senseonics focuses on the development and manufacturing of glucose monitoring products for people with diabetes, using differentiated, long‑term implantable glucose management technology. The company’s common stock is listed on the Nasdaq Global Select Market under the ticker symbol SENS, following a transfer from the NYSE American that became effective in November 2025.

Senseonics’ core offerings are its Eversense continuous glucose monitoring (CGM) systems, specifically Eversense 365 and Eversense E3. These systems are designed for people with diabetes aged 18 and older and are indicated for continually measuring glucose levels for up to 365 days (Eversense 365) and 180 days (Eversense E3). Each system uses a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. Glucose data are automatically sent every five minutes to a mobile app on the user’s smartphone, providing ongoing insights into glucose trends.

The company describes Eversense 365 as the world’s first and only year‑long CGM system, offering a long sensor wear duration that reduces the need for frequent sensor changes. Eversense 365 and Eversense E3 are prescription devices, and the sensor insertion and removal procedures are performed by a health care provider. The systems are indicated to replace fingerstick blood glucose measurements for diabetes treatment decisions, although fingerstick measurements are still required for calibration and in certain clinical situations, such as when symptoms do not match CGM readings or when taking medications of the tetracycline class.

Senseonics reports that its CGM systems are designed to serve the global diabetes community by offering a long‑term implantable option that differs from traditional short‑term CGMs. Company communications highlight that Eversense 365 aims to help patients overcome common frustrations and interruptions associated with shorter‑duration CGM sensors, allowing users to focus on managing their diabetes rather than frequently changing sensors and re‑pairing devices.

In addition to its product platform, Senseonics has described a business structure centered on glucose monitoring products. Earlier descriptions reference a glucose monitoring product segment and components such as a continuous glucose monitoring system, sensor, smart transmitter, and mobile app. More recent company statements emphasize long‑term implantable CGM systems and the integration of development and manufacturing activities around Eversense 365 and Eversense E3.

Senseonics has also been involved in commercialization arrangements for Eversense products. Under a collaboration that began in 2020, Ascensia Diabetes Care held exclusive global distribution rights for Eversense, including Eversense 365. In 2025, Senseonics and Ascensia announced a memorandum of understanding and related plans under which commercial activities for Eversense 365 and future products would transition to Senseonics, with Senseonics assuming responsibility for global sales, marketing, and commercialization in the United States beginning January 1, 2026, and using transition service agreements for markets outside the U.S. Company communications state that this unification of development, manufacturing, and commercialization within Senseonics is intended to support the growth potential of Eversense.

Senseonics has also highlighted the integration of its CGM technology with automated insulin delivery (AID) systems. In collaboration with Sequel MedTech, the company announced that the twiist AID system became the first AID system compatible with Eversense 365. The integrated use of twiist with Eversense 365 is described as providing people with type 1 diabetes a new level of flexibility and personalization in diabetes management, with Eversense 365 supplying continuous glucose data to support automated insulin delivery decisions.

From a corporate actions perspective, Senseonics has undertaken steps related to its capital structure and exchange listing. In 2025, stockholders approved a reverse stock split within a specified range, and the company subsequently implemented a 1‑for‑20 reverse stock split, as described in its filings. The company also filed a Form 25 in November 2025 to voluntarily remove its common stock from listing and registration on the NYSE American in connection with the transfer of its listing to Nasdaq.

Business Focus and Technology

Across its public communications, Senseonics consistently describes itself as a medical technology company focused on glucose monitoring products for people with diabetes. The company emphasizes long‑term, implantable CGM systems that use an under‑the‑skin sensor, an external smart transmitter, and a smartphone app. These systems are designed to provide frequent, automated glucose readings and to support diabetes treatment decisions under the supervision of health care providers.

Regulatory Indications and Use

Senseonics’ disclosures specify that the Eversense CGM Systems are indicated for adults with diabetes and can be used to replace fingerstick blood glucose measurements for treatment decisions, subject to calibration requirements and specific clinical circumstances. The systems are prescription devices, and health care providers perform the sensor insertion and removal procedures. This framework underscores the company’s role in producing regulated medical devices for chronic disease management.

Capital Markets and Corporate Governance

Senseonics is incorporated in Delaware and has filed multiple reports with the U.S. Securities and Exchange Commission, including Form 8‑K reports describing financial results, business updates, and corporate actions such as the reverse stock split and special stockholder meeting. The company’s special meeting materials in 2025 describe the rationale for authorizing a reverse stock split and associated reduction in authorized shares of common stock.

Position Within the Medical Device Sector

Within the broader manufacturing sector, Senseonics is classified in surgical and medical instrument manufacturing. Its focus on long‑term implantable CGM systems places it in the subset of companies developing medical devices for diabetes monitoring and management. Company statements emphasize the goal of transforming lives in the diabetes community through differentiated, long‑term implantable glucose management technology.

Key Products Mentioned in Public Disclosures

• Eversense 365 – a continuous glucose monitoring system indicated for up to 365 days of use in adults with diabetes, using an implantable sensor, smart transmitter, and mobile app.
• Eversense E3 – a continuous glucose monitoring system indicated for up to 180 days of use in adults with diabetes, also using an implantable sensor, smart transmitter, and mobile app.
• Glucose monitoring product segment – as referenced in earlier descriptions, encompassing the CGM system, sensor, smart transmitter, and mobile app.

Stock Status and Exchange History

Senseonics’ common stock has traded under the symbol SENS. Company announcements state that the stock was listed on the NYSE American and that the company decided to transfer the listing to the Nasdaq Global Select Market. A Form 25 filing in November 2025 documents the voluntary withdrawal of the class of securities from listing and registration on the NYSE American under the applicable SEC rule, in connection with this transfer.

Risk and Regulatory Disclosures

Senseonics’ public filings and press releases include forward‑looking statements and risk factor references, noting that actual results may differ from projections due to various factors. The company refers readers to its Annual Report on Form 10‑K and Quarterly Reports on Form 10‑Q for detailed risk factors related to its business, regulatory environment, and financial condition.

Summary

In summary, Senseonics Holdings, Inc. is a publicly traded medical technology company in the surgical and medical instrument manufacturing sector. It focuses on the development and manufacturing of long‑term, implantable continuous glucose monitoring systems, particularly Eversense 365 and Eversense E3, for adults with diabetes. Its technology combines an under‑the‑skin sensor, a smart transmitter, and a smartphone app to provide frequent, automated glucose readings. The company has engaged in commercialization partnerships and has taken corporate actions such as a reverse stock split and a transfer of its stock exchange listing, as documented in its SEC filings and press releases.